Skip to main content

Market Overview

Recap: Corbus Pharmaceuticals Q1 Earnings



Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) were unchanged after the company reported Q1 results.

Quarterly Results

Earnings per share increased 67.44% year over year to ($0.14), which beat the estimate of ($0.15).

Revenue of $647,824 decreased by 63.23% from the same period last year, which missed the estimate of $960,000.


Earnings guidance hasn't been issued by the company for now.

Corbus Pharmaceuticals hasn't issued any revenue guidance for the time being.

Recent Stock Performance

52-week high: $9.78

Company's 52-week low was at $0.91

Price action over last quarter: down 31.65%

Company Profile

Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune system. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.


Related Articles (CRBP)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at